B cells as a therapeutic target in autoimmune diseases

Bibliography

• NAPARSTEK Y, PLOTZ PH: The role of autoantibodies in autoimmune disease. Ann. Rev. Immunol (1993) 11:79–104.
   PubMed Web of Science ®Google Scholar
• HOLERS VM: The complement system as a therapeutic target in autoimmunity. Clin. Immunol (2003) 107(3):140–151.
   PubMed Web of Science ®Google Scholar
• VAN DE WINKEL JG, CAPEL PJ: Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today (1993) 14(5):215–221.
   PubMedGoogle Scholar
• TAKAI T: Roles of Fc receptors in autoimmunity. Nat. Rev Immunol (2002) 2(8):580–592.
   PubMed Web of Science ®Google Scholar
• SAMUELSSON A, TOWERS TL, RAVETCH JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science (2001) 291(5503):484–486.
   PubMed Web of Science ®Google Scholar
• BRUHNS P, SAMUELSSON A, POLLARD JW, RAVETCH JV: Colony-stimulating factor- 1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity (2003) 18(4):573–581.
   PubMed Web of Science ®Google Scholar
• WEYAND CM, KANG YM, KURTIN PJ, GORONZY JJ: The power of the third dimension: tissue architecture and autoimmunity in rheumatoid arthritis. Curc Opin. Rheumatol (2003) 15(3):259–266.
   PubMed Web of Science ®Google Scholar
• KLIMIUK PA, GORONZY JJ, BJOR NSSON J, BECKENBAUGH RD, WEYAND CM: Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am. J. Pathol (1997) 151(5):1311–1319.
   PubMed Web of Science ®Google Scholar
• TAKEMURA S, KLIMIUK PA, BRAUN A, GORONZY JJ, WEYAND CM: T cell activation in rheumatoid synovium is B cell dependent. Immunol (2001) 167(8):4710–4718.
   Web of Science ®Google Scholar
• HUTCHINGS P, RAYNER DC, CHAMPION BR et al: High efficiency antigen presentation by thyroglobulin-primed murine splenic B cells. Eur. Immunol (1987) 17(3):393–398.
   PubMed Web of Science ®Google Scholar
• GORONZY JJ, WEYAND CM: Rheumatoid Arthritis. Immunol Rev (2005) 204:55–73.
   PubMed Web of Science ®Google Scholar
• WEYAND CM, KURTIN PJ, GORONZY JJ: Ectopic lymphoid organogenesis: a fast track for autoimmunity. Am. J. Pathol (2001) 159(3):787–793.
   PubMed Web of Science ®Google Scholar
• TAKEMURA S, BRAUN A, CROWSON C et al: Lymphoid neogenesis in rheumatoid synovitis. Immunol (2001) 167(2):1072–1080.
   Web of Science ®Google Scholar
• KANG YM, ZHANG X, WAGNER UG et al: CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J. Exp. Med. (2002) 195(10):1325–1336.
   PubMed Web of Science ®Google Scholar
• WAGNER UG, KURTIN PJ, WAHNER A et al.: The role of CD8+ CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis. Immunol (1998) 161(10:6390–6397.
   Google Scholar
• MARTINEZ-TABOADA V, BRACK A, HUNDER GG, GORONZY JJ, WEYAND CM: The inflammatory infiltrate in giant cell arteritis selects against B lymphocytes. J. Rheumatol (1996) 23(6):1011–1014.
   PubMed Web of Science ®Google Scholar
• SILVERMAN GJ, WEISMAN S: Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. (2003) 48(6):1484–1492.
   PubMed Web of Science ®Google Scholar
• GRILLO-LOPEZ AJ: Rituximab: an insider's historical perspective. Semin. Oncol (2000) 27(6 Suppl. 12):9–16.
   Google Scholar
• COPE AP, FELDMANN M: Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Curr. Opin. Immunol (2004) 16(6):780–786.
   PubMed Web of Science ®Google Scholar
• REFF ME, CARNER K, CHAMBERS KS et al: Depletion of B cells in viva by a chimeric mouse human monoclonal antibody to CD20.Blood (1994) 83(2):435–445.
   PubMed Web of Science ®Google Scholar
• ALAS S, BONAVIDA B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/ paracrine loop and results in down-regulation of Bc1-2 and sensitization to cytotoxic drugs. Cancer Res. (2001) 61(13):5137–5144.
   PubMed Web of Science ®Google Scholar
• MATHAS S, RICKERS A, BOMMERT K, DORKEN B, MAPARA MY: Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. (2000) 60(24):7170–7176.
   PubMed Web of Science ®Google Scholar
• TSOKOS GC: B cells, be gone-B-cell depletion in the treatment of rheumatoid arthritis. N Engl. I Med. (2004) 350(25):2546–2548.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood(1997) 90(6):2188–2195.
   PubMed Web of Science ®Google Scholar
• SALEH MN, GUTHEIL J, MOORE M et al: A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semi]. Oncol (2000) 27(6 Suppl. 12):99–103.
   Google Scholar
• RATANATHARATHORN V, CARSON E, REYNOLDS C et al: Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann. Intern. Med. (2000) 133(4):275–279.
   PubMed Web of Science ®Google Scholar
• ZECCA M, DE STEFANO P, NOBILI B, LOCATELLI F: Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood (2001) 97(12):3995–3997.
   PubMed Web of Science ®Google Scholar
• AHRENS N, KINGREEN D, SELTSAM A, SALAMA A: Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). BE J. Haematol (2001) 114(1):244–245.
   PubMed Web of Science ®Google Scholar
• BERENTSEN S, TJONNFJORD GE, BRUDEVOLD R et al: Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. BE J. Haematol (2001) 115(1):79–83.
   PubMed Web of Science ®Google Scholar
• LAYIOS N, VAN DEN NESTE E, JOST Eet al.: Remission of severe cold agglutinin disease after Rituximab therapy. Leukemia (2001) 15(1):187–188.
   Google Scholar
• STASI R, PAGANO A, STIPA E, AMADORI S: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood (2001) 98(4):952–957.
   PubMed Web of Science ®Google Scholar
• SPECKS U, FERVENZA FC, MCDONALD TJ, HOGAN MC: Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. (2001) 44(12):2836–2840.
   PubMed Web of Science ®Google Scholar
• EDWARDS JC, CAMBRIDGE G: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) (2001) 40(2):205–211.
   PubMed Web of Science ®Google Scholar
• MARTIN F, CHAN AC: Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity (2004) 20(5):517–527.
   PubMed Web of Science ®Google Scholar
• WEYAND CM, GORONZY JJ, TAKEMURA S, KURTIN PJ: Cell-cell interactions in synovitis. Interactions between T cells and B cells in rheumatoid arthritis. Arthritis Res. (2000) 2(6):457–463.
   Google Scholar
• CARSON DA, CHEN PP, KIPPS TJ: New roles for rheumatoid factor. J. Invest. (1991) 87(2):379–383.
   Google Scholar
• ROOSNEK E, LANZAVECCHIA A: Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J. Exp. Med. (1991) 173(2):487–489.
   PubMed Web of Science ®Google Scholar
• LANZAVECCHIA A: Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Ann. Rev Immunol (1990) 8:773–793.
   PubMed Web of Science ®Google Scholar
• ZHANG Z, BRIDGES SL, JR.: Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum. Dis. Clin. North Am. (2001) 27(2):335–353.
   Google Scholar
• GRETZ JE, ANDERSON AO, SHAW S: Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex. Immunol Rev (1997) 156:11–24.
   PubMed Web of Science ®Google Scholar
• LEANDRO MJ, EDWARDS JC, CAMBRIDGE G: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. (2002) 61(10):883–888.
   PubMed Web of Science ®Google Scholar
• DE VITA S, ZAJA F, SACCO S et al: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. (2002) 46(8):2029–2033.
   PubMed Web of Science ®Google Scholar
• EDWARDS JC, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. (2004) 350(25):2572–2581.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN P, HAGEMEISTER FB, GRILLO-LOPEZ AJ: Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin. Oncol (1999) 26(5 Suppl. 14):79–87.
   Google Scholar
• EMERY P, SHEERAN T, LEHANE PB, SAIEDABADI N, SHAW TM: Efficacy and Safety of Rituximab at 2 Years Following a Single Treatment in Patients with Active Rheumatoid Arthritis. Arthritis Rheum. (2004) 50(Suppl.):51762.
   Google Scholar
• CAMBRIDGE G, LEANDRO MJ, STOHL W et al: Serological Changes Following B Cell Depletion Therapy in Systemic Lupus Erythematosus: Relationship with BLyS. Arthritis Rheum. (2004) 50(Suppl.):51723.
   Google Scholar
• NG HJ, LIM LC: Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann. Hematol (2001) 80(9):549–552.
   PubMed Web of Science ®Google Scholar
• SONG KW, MOLLEE P, PATTERSON B, BRIEN W, CRUMP M: Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br. Haematol (2002) 119(1):125–127.
   PubMed Web of Science ®Google Scholar
• SHARMA VR, FLEMING DR, SLONE SP: Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood (2000) 96(3):1184–1186.
   PubMed Web of Science ®Google Scholar
• PERROTTA S, LOCATELLI F, LA MANNA A et al: Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. BL J. Haematol (2002) 116(2):465–467.
   PubMed Web of Science ®Google Scholar
• LEANDRO MJ, EDWARDS JC, CAMBRIDGE G, EHRENSTEIN MR, ISENBERG DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. (2002) 46(10):2673–2677.
   PubMed Web of Science ®Google Scholar
• ANOLIK JH, CAMPBELL D, FELGAR RE et al.: The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. (2003) 48(2):455–459.
   PubMed Web of Science ®Google Scholar
• LOONEY RJ, ANOLIK JH, CAMPBELL D et al: B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. (2004) 50(8):2580–2589.
   PubMed Web of Science ®Google Scholar
• TOKUNAGA M, FUJII K, SAITO K et al: Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) (2004) 44(2):176–182.
   PubMed Web of Science ®Google Scholar
• ANOLIK JH, BARNARD J, CAPPIONE A et al: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. (2004) 50(10:3580–3590.
   PubMedGoogle Scholar
• KNEITZ C, WILHELM M, TONY HP: Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology (2002) 206(5):519–527.
   Google Scholar
• LEE EJ, KUECK B: Rituxan in the treatment of cold agglutinin disease. Blood (1998) 92(9):3490–3491.
   PubMed Web of Science ®Google Scholar
• GIAGOUNIDIS AA, ANHUF J, SCHNEIDER P et al.: Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur. Haematol (2002) 69(2):95–100.
   PubMed Web of Science ®Google Scholar
• PATEL K, BERMAN J, FERBER A, CARO J: Refractory autoimmune thrombocytopenic purpura treatment with Rituximab. Am. J. Hematol (2001) 67(1):59–60.
   PubMed Web of Science ®Google Scholar
• DELGADO J, BUSTOS JG, JIMENEZ-YUSTE V, HERNANDEZ-NAVARRO F: Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura. Haematologica (2002) 87(2):215–216.
   PubMed Web of Science ®Google Scholar
• NARANG M, PENNER JA, WILLIAMS D: Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). Am. J. Hematol (2003) 74(4):263–267.
   PubMed Web of Science ®Google Scholar
• COOPER N, STASI R, CUNNINGHAM-RUNDLES S et al: The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. BL I Haematol (2004) 125(2):232–239.
   PubMed Web of Science ®Google Scholar
• KOULOVA L, ALEXANDRESCU D, DUTCHER JP et al.: Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am. Hematol (2005) 78(1):49–54.
   PubMed Web of Science ®Google Scholar
• CAMBRIDGE G, LEANDRO MJ, EDWARDS JC et al: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. (2003) 48(8):2146–2154.
   PubMed Web of Science ®Google Scholar
• LIOSSIS SN, SFIKAKIS PP: Costimulation blockade in the treatment of rheumatic diseases. BioDrugs (2004) 18(2):95–102.
   PubMed Web of Science ®Google Scholar
• MOORE PA, BELVEDERE 0, ORR A et al.: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 285(5425):260–263.
   Google Scholar
• MUKHOPADHYAY A, NI J, ZHAI Y, YU GL, AGGARWAL BB: Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. I Biol. Chem. (1999) 274(23):15978–15981.
   Web of Science ®Google Scholar
• SCHNEIDER P, MACKAY F, STEINER V et al.: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. I Exp. Med. (1999) 189(10:1747–1756.
   PubMedGoogle Scholar
• MACKAY F, SCHNEIDER P, RENNERT P, BROWNING J: BAFF AND APRIL: a tutorial on B cell survival. Ann. Rev Immunol (2003) 21:231–264.
   PubMed Web of Science ®Google Scholar
• MARSTERS SA, YAN M, PITTI RM et al.: Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr. Biol. (2000) 10(13):785–788.
   PubMed Web of Science ®Google Scholar
• GROSS JA, JOHNSTON J, MUDRI S et al.: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 404(6781):995–999.
   PubMed Web of Science ®Google Scholar
• THOMPSON JS, SCHNEIDER P, KALLED SL et al.: BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. I Exp. Med. (2000) 192(1):129–135.
   PubMed Web of Science ®Google Scholar
• SHU HB, JOHNSON H: B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1.Proc. Natl. Acad. Li. USA (2000) 97(16):9156–9161.
   Google Scholar
• YU G, BOONE T, DELANEY J et al.: APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunol (2000) 1(3):252–256.
   PubMed Web of Science ®Google Scholar
• WU Y, BRESSETTE D, CARRELL JA et al.: Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. I Biol. Chem. (2000) 275(45):35478–35485.
   Web of Science ®Google Scholar
• THOMPSON JS, BIXLER SA, QIAN F et al.: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science (2001) 293(5537):2108–2111.
   PubMed Web of Science ®Google Scholar
• LOCKSLEY RM, KILLEEN N, LENARDO MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 104(4):487–501.
   PubMed Web of Science ®Google Scholar
• ROSCHKE V, SOSNOVTSEVA S, WARD CD et al.: BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. Immunol (2002) 169(8):4314–4321.
   Web of Science ®Google Scholar
• AVERY DT, KALLED SL, ELLYARD JI et al: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. (2003) 112(2):286–297.
   PubMed Web of Science ®Google Scholar
• DO RK, HATADA E, LEE H et al.: Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. I Exp. Med. (2000) 192(7):953–964.
   PubMed Web of Science ®Google Scholar
• GORELIK L, CUTLER AH, THILL G et al: Cutting edge: BAFF regulates CD21/ 35 and CD23 expression independent of its B cell survival function. J. Immunol (2004) 172(2):762–766.
   PubMed Web of Science ®Google Scholar
• HASE H, KANNO Y, KOJIMA M et al.: BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood (2004) 103(6):2257–2265.
   PubMed Web of Science ®Google Scholar
• SCHIEMANN B, GOMMERMAN JL, VORA K et al.: An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science (2001) 293(5537):2111–2114.
   PubMed Web of Science ®Google Scholar
• MACKAY F, WOODCOCK SA, LAWTON P et al: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. I Exp. Med. (1999) 190(11):1697–1710.
   PubMed Web of Science ®Google Scholar
• BATTEN M, GROOM J, CACHERO TG et al: BAFF mediates survival of peripheral immature B lymphocytes. I Exp. Med. (2000) 192(10):1453–1466.
   PubMed Web of Science ®Google Scholar
• YAN M, MARSTERS SA, GREWAL IS et al: Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat. Immunol (2000) 1(1):37–41.
   PubMed Web of Science ®Google Scholar
• RAHMAN ZS, RAO SP, KALLED SL, MANSER T: Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. I Exp. Med. (2003) 198(8):1157–1169.
   PubMed Web of Science ®Google Scholar
• RAHMAN ZS, MANSER T: B cells expressing Bc1-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. I Immunol (2004) 173(10):6179–6188.
   PubMed Web of Science ®Google Scholar
• HAHNE M, KATAOKA T, SCHROTER M et al: APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. I Exp. Med. (1998) 188(6):1185–1190.
   PubMed Web of Science ®Google Scholar
• RENNERT P, SCHNEIDER P, CACHERO TG et al.: A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. I Exp. Med. (2000) 192(11):1677–1684.
   PubMed Web of Science ®Google Scholar
• MEDEMA JP, PLANELLES-CARAZO L, HARDENBERG G, HAHNE M: The uncertain glory of APRIL. Cell Death Differ. (2003) 10(10):1121–1125.
   PubMed Web of Science ®Google Scholar
• VARFOLOMEEV E, KISCHKEL F, MARTIN F et al.: APRIL-deficient mice have normal immune system development. Mol. Cell. Biol. (2004) 24(3):997–1006.
   PubMed Web of Science ®Google Scholar
• LEADBETTER EA, RIFKIN IR, HOHLBAUM AM et al.: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature (2002) 416(6881):603–607.
   PubMed Web of Science ®Google Scholar
• RAMANUJAM M, DAVIDSON A: The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res. Ther. (2004) 6(5):197–202.
   PubMed Web of Science ®Google Scholar
• KOLFSCHOTEN GM, PRADET-BALADE B, HAHNE M, MEDEMA JP: TWE-PRIL: a fusion protein of TWEAK and APRIL. Biochem. Pharmacol. (2003) 66(8):1427–1432.
   PubMed Web of Science ®Google Scholar
• HUARD B, ARLETTAZ L, AMBROSE C et al: BAFF production by antigen-presenting cells provides T cell co-stimulation. [nt. Immunol (2004) 16(3):467–475.
   PubMed Web of Science ®Google Scholar
• STEIN JV, LOPEZ-FRAGA M, ELUSTONDO FA et al: APRIL modulates B and T cell immunity. I OM Invest. (2002) 109(12):1587–1598.
   Google Scholar
• WANG H, MARSTERS SA, BAKER T et al: TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat. Immunol (2001) 2(7):632–637.
   PubMed Web of Science ®Google Scholar
• SESHASAYEE D, VALDEZ P, YAN M et al.: Loss of TACT causes fatal lymphoproliferation and autoimmunity, establishing TACT as an inhibitory BLyS receptor. Immunity (2003) 18(2):279–288.
   PubMed Web of Science ®Google Scholar
• CHEEMA GS, ROSCHKE V, HILBERT DM, STOHL W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. (2001) 44(6):1313–1319.
   PubMed Web of Science ®Google Scholar
• GROOM J, KALLED SL, CUTLER AH et al.: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. Clin. Invest. (2002) 109(1):59–68.
   Google Scholar
• BAKER KP, EDWARDS BM, MAIN SH et al.: Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. (2003) 48(10:3253–3265.
   PubMedGoogle Scholar
• RAMANUJAM M, WANG X, HUANG W et al.: Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. ./. Immunol (2004) 173(5):3524–3534.
   PubMed Web of Science ®Google Scholar
• SEYLER T, TAKEMURA S, KANG YM et al.: Biological functions of BLyS and APRIL in rheumatoid synovitis. Arthritis Rheum. (2003) 48:S457.
   Google Scholar
• BERNASCONI NL, ONAI N, LANZAVECCHIA A: A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood (2003) 101(10:4500–4504.
   PubMedGoogle Scholar
• VIGLIANTI GA, LAU CM, HANLEY TM et al: Activation of autoreactive B cells by CpG dsDNA. Immunity (2003) 19(6):837–847.
   PubMed Web of Science ®Google Scholar
• ICHIKAWA HT, WILLIAMS LP, SEGAL BM: Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J. Immunol (2002) 169(5):2781–2787.
   PubMed Web of Science ®Google Scholar
• GORONZY JJ, WEYAND CM: T-cell regulation in rheumatoid arthritis. Curr. Opin. Rheumatol (2004) 16(3):212–217.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, ALTEN R, VAN DEN BOSCH F et al: Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. (2002) 46(6):1470–1479.
   PubMed Web of Science ®Google Scholar
• KREMER JM, WESTHOVENS R, LEON M et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl. I Med. (2003) 349(20):1907–1915.
   PubMed Web of Science ®Google Scholar
• PELTOMAA R, PAIMELA L, KAUTIAINEN H, LEIRISALO-REPO M: Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann. Rheum. Dis. (2002) 61(10):889–894.
   PubMedGoogle Scholar